1. (2019) Prescribed drug spending in Canada, 2019: a focus on public drug programs (Canadian Institute for Health Information, Ottawa) Available: www.cihi.ca/en/prescribed-drug-spending-in-canada-2019 . accessed 2020 Dec. 1.
2. Kobelt G Kasteng F (2009) Access to innovative treatments in rheumatoid arthritis in Europe: a report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA) (Lund University, European Federation of Pharmaceutical Industry Associations, Sweden) Available: http://www.comparatorreports.se/Access%20to%20RA%20Treatments%20October%202009.pdf . accessed 2020 Dec. 1.
3. Decomposition analysis of spending and price trends for biologic antirheumatic drugs in Medicare and Medicaid;McCormick;Arthritis Rheumatol,2020
4. Norway, biosimilars in different funding systems. What works?
5. Biosimilar cost savings in the United States: initial experience and future potential;Mulcahy;Rand Health Q,2018